CASI Pharmaceuticals (NASDAQ:CASI) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares CASI Pharmaceuticals and INmune Bio’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CASI Pharmaceuticals||$4.13 million||66.32||-$46.03 million||($0.42)||-5.26|
|INmune Bio||N/A||N/A||-$7.68 million||($0.75)||-11.91|
Volatility & Risk
CASI Pharmaceuticals has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, INmune Bio has a beta of 2.98, meaning that its stock price is 198% more volatile than the S&P 500.
This is a breakdown of current ratings and price targets for CASI Pharmaceuticals and INmune Bio, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CASI Pharmaceuticals presently has a consensus price target of $4.25, indicating a potential upside of 92.31%. INmune Bio has a consensus price target of $19.25, indicating a potential upside of 115.57%. Given INmune Bio’s higher possible upside, analysts plainly believe INmune Bio is more favorable than CASI Pharmaceuticals.
Institutional & Insider Ownership
18.1% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.7% of INmune Bio shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 58.9% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares CASI Pharmaceuticals and INmune Bio’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
INmune Bio beats CASI Pharmaceuticals on 8 of the 12 factors compared between the two stocks.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.
About INmune Bio
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was founded in 2015 and is headquartered in La Jolla, California.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.